Table 2.

Follow‐up and outcome of booster administration with mRNA COVID‐19 vaccine

No.	Age (y), sex	Booster vaccination
		Vaccine type	Vaccination protocol	Antihistamines	Outcome	Late onset symptoms (>24 h)
1	47, f	mRNA‐1273	2‐step administration	Yes	Ear redness after 1st dose	Urticaria 24 h after vaccination
2	42, f	mRNA‐1273	2‐step administration	Yes	No allergic symptoms	‐
3	30, m	No booster vaccination
4	43, f	mRNA‐1273	2‐step administration	Yes	Pruritus after 1st dose*	‐
5	26, f	No booster vaccination
6	56, f	mRNA‐1273	2‐step Administration	Yes	No allergic symptoms	‐
7	43, f	mRNA‐1273	Unfractionated	Yes	No allergic symptoms	‐
8	56, f	mRNA‐1273	Unfractionated	Yes	No allergic symptoms	‐
9	50, f	mRNA‐1273	Unfractionated	Yes	Tongue burning*	‐
10	60, f	mRNA‐1273	Unfractionated	Yes	Burning sensation of the skin, swallowing problems*	‐
11	32, f	No booster vaccination
12	20, m	mRNA‐1273	Unfractionated	No	No allergic symptoms	‐
13	56, f	mRNA‐1273	Unfractionated	Yes	No allergic symptoms	‐
14	53, f	BNT 162B2	Unfractionated	YES	No allergic symptoms	‐
15	37, f	mRNA‐1273	Unfractionated	Yes	No allergic symptoms	‐
16	58, m	No booster vaccination
17	42, f	mRNA‐1273	Unfractionated	Yes	No allergic symptoms	Urticaria 5 d after vaccination

Abbreviations and specification: f, female; d, day(s); h, hour(s); m, male; *spontaneous improvement without therapy.